Diversion Control Division, US Department of Justice, Drug Enforcement Administration

Manufacturers Notice of Application - 2005

FR Doc 05-6589 [Federal Register: April 4, 2005 (Volume 70, Number 63)] [Notices] [Page 17124-17125] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr04ap05-134]


Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Application

Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on January 4, 2005, Mallinckrodt Inc., Mallinckrodt & Second Streets, St. Louis, Missouri 63147, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II:

Drug  Schedule 
Tetrahydrocannabinols (7370)   I
Codeine-N-oxide (9053)   I
Dihydromorphine (9145)   I
Difenoxin (9168)   I
Heroin (9200)   I
Morphine-N-oxide (9307)   I
Nicomorphine (9312)   I
Normorphine (9313)   I
Norlevorphanol (9634)   I
Amphetamine (1100)   II
Methamphetamine (1105)   II
Methylophenidate (1724)   II
Codeine (9050)   II
Diprenorphine (9058)   II
Etorphine HCL (9059)   II
Dihydrocodeine (9120)   II
Hydromorphone (9150)   II
Oxycodone (9143)   II
Diphenoxylate (9170)   II
Benzoylecgonine (9180)   II
Hydrocodone (9193)   II
Levorphanol (9220)   II
Meperidine (9230)   II
Methadone (9250)   II
Methadone Intermediate (9254)   II
Metopon (9260)   II
Dextropropoxyphene (9273)   II
Morphine (9300)   II
Thebaine (9333)   II
Opium extracts (9610)   II
Opium fluid extract (9620)   II
Opium tincture (9630)   II
Opium, powdered (9639)   II
Opium, granulated (9640)   II
Levo-alphacetylmethadol (9648)   II
Oxymorphone (9652)   II
Alfentanil (9737)   II
Remifentanil (9739)   II
Sufentanil (9740)   II
Fentanyl (9801)   II

The company plans to manufacture the listed controlled substances for internal use and for distribution to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative, Liaison and Policy Section (ODL); or any being sent via express mail should be sent to

[[Page 17125]]

DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than June 3, 2005.

Dated: March 25, 2005.

William J. Walker, 
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 05-6589 Filed 4-1-05; 8:45 am]



NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Printing Office (GPO).

Emergency Disaster Relief
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility